Here’s how ASX healthcare shares performed in FY22

ASX healthcare shares took a massive plunge from the restart of trade in January.

| More on:
Two staff in a medical research laboratory wearing masks and caps work on their tests, representing the performance of ASX healthcare shares in FY22

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX healthcare shares were nothing short of a mixed bunch in FY22
  • As a group, healthcare shares performed poorly after incurring losses from January to June
  • As a result, many individual names also struggled on the ASX charts in FY22

ASX healthcare shares were a mixed basket this past financial year.

After a healthy first half of FY22, the sector took a massive plunge from the restart of trade in January.

The S&P/ASX 200 Health Care Index (ASX: XHJ) fell around 5% into the red for the 12 months to June 30. It traded in sideways territory from January to June.

These three healthcare shares are worthy of note. Let’s take a look at each one.

CSL Limited (ASX: CSL)

The biotech giant is a natural on this list. It suffered a similar fate to the wider sector on the charts in FY22.

After soaring to a 52-week high price of $318 on 24 November, ASX investors sold CSL down to a 52-week low of $243 per share by February.

CSL announced its acquisition offer for Vifor Pharma in December last year. It issued US$4 billion of bonds in the US debt capital markets to finance the transaction.

The six issued notes pay a coupon ranging from 3.85% to 4.95% per annum and range from five years to 40 years in tenor.

The CSL share price finished FY22 in a bullish uptrend that has continued into the new financial year. It is down 3.5% in 2022 so far and trading at $285.66 at the time of writing.

ResMed CDI (ASX: RMD)

Sleep treatment company ResMed recognised a series of losses in FY22.

ResMed reversed out of a bullish uptrend in late 2021. The ResMed share price fell from a high of $40.28 on 13 September to a 52-week low of $27.63 in May.

Despite its struggles, several analysts rate the ResMed share price a buy. Fundamentally, they say, the company is strong, and its long-term outlook is attractive.

Morgans is bullish on ResMed and says “nothing changes our medium/longer term view that the company remains well-placed as it builds a unique, patient-centric, connected-care digital platform.”

Meanwhile, analysts at HB Insights are also bullish. They reckon a product recall by ResMed’s competitor is a boon for the company.

This ASX healthcare share is trading down 0.92% today at $32.20.

Immutep Ltd (ASX: IMM)

Finally, Immutep is worth a mention in this list. The developer of LAG-3 immunotherapy cancer treatments had a choppy year and landed deep in the red.

Nevertheless, it released several updates across the 12 months regarding its flagship label, known as etfi.

Etfi gained more clinical trial momentum in FY22. It was most recently recognised at the American Society of Clinical Oncology 2022 special edition.

However, ASX investors appear to have overlooked this clinical progress, and have traded the Immutep share price down to a 52-week low of 29 cents on 30 June.

It has now levelled back up to trade at 32 cents.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two healthcare workers, a male doctor in the background with a woman in scrubs in the foreground,, smile towards the camera against a plain backdrop.
Broker Notes

5 reasons to buy this ASX healthcare share: Goldman Sachs

This could be the healthcare share to buy right now...

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Up 8% in July, is there more upside in the CSL share price this earnings season?

CSL is forecast to benefit from an improved outlook for plasma collections.

Read more »

A dollar sign embedded in ice, indicating a share price freeze or trading halt
Healthcare Shares

Why is the Mesoblast share price on ice today?

Mesoblast is another share placed on pause today.

Read more »

Woman holding out her hand, symbolising a trading halt.
Healthcare Shares

Medical Developments share price halted amid ‘significant near-term opportunities’

The company seeks to raise additional capital.

Read more »

A woman stretches her arms into the sky as she rises above the crowd.
Healthcare Shares

Up 22% in a month, can the Imugene share price extend its rally?

Imugene extends its gains today.

Read more »

Doctor reading a file
Healthcare Shares

What’s been impacting the Ramsay Health share price this week?

The hospital operator has decided to go its own way...

Read more »

medical asx share price represented by doctor giving thumbs up
Share Gainers

Why is the Avita Medical share price tracking 20% higher today?

Shares in the regenerative medicine company continue their gains, tracking higher over the past month.

Read more »

Broker Notes

Why Citi just became even more bullish on the CSL share price

This healthcare share could be a quality option for investors...

Read more »